SNCA protein, alpha-Synuclein Delta-NAC recombinant protein

Alphabetical Listing of Primary Antibodies:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Alphabetical Listing of Proteins:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Peptides \| Secondary Antibodies \| ELISA Kits

alpha-Synuclein Delta-NAC recombinant protein

Catalog Number: 10-002-38065

Buy SNCA protein -

Size:

Related Product Names:

- SNCA protein; SNCA; NACP; PARK1; alpha-Synuclein Delta-NAC
- alpha-Synuclein Delta-NAC, Human, Recombinant, E Coli; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Alpha-synuclein

- Gene Information - Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.

Gene Name: SNCA	Gene Name Synonym: NACP; PARK1
Gi #: N/A	NCBI Acc #: NP_000336.1	Swiss Prot Acc #: P37840
Length (aa): N/A	Mol. Weight (Da): 14460	Chrom Location: N/A

Sequence: MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK GTEIWMKKDQ LGKNEEGAPQ EGILEDMPVD PDNEAYEMPS EEGYQDYEPE A

Concentration: 1mg/ml

Purity/Purification: >= 95% by SDS PAGE

Format: Liquid. In 20 mM Tris-HCl buffer (pH 7.5) containing 0.1 M NaCl

Storage: Store at -20C.

Shipping: Products may be shipped on ice pack or dry ice.

TESTING: (secondary reagents and protocols )

WB ( anti-SNCA protein )

SNCA protein image
SNCA

SNCA PROTEIN TARGET DESCRIPTION:

Synonym Names for SNCA protein: SNCA; NACP; PARK1; alpha-Synuclein Delta-NAC, Human, Recombinant, E Coli; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP; Alpha-synuclein

A deletion mutant of alpha-synuclein that lacks the NAC region (amino acid 61-95). alpha-synuclein (deltaNAC) was overexpressed in E. coli and purified to apparent homogeneity by taking advantage of the thermosolubility of the protein and by using conventional column chromatography techniques. 6 amino acids were added as a linker

Function: May be involved in the regulation of dopamine release and transport. Soluble protein, normally localized primarily at the presynaptic region of axons, which can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation.

Subunit: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones.

Subcellular Location: Cytoplasm. Membrane. Nucleus. Note=Membrane-bound in dopaminergic neurons. Also found in the nucleus.

Tissue Specificity: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.

Domain: The NAC domain is involved in the fibril formation. The middle region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.

Ptm: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.

Ptm: Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.

Ptm: Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).

Disease: Defects in SNCA are a cause of autosomal dominant Parkinson disease 1 (PARK1) [MIM:168601, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

Disease: Defects in SNCA are the cause of Parkinson disease 4 (PARK4) [MIM:605543, 168600].

Disease: Defects in SNCA are the cause of Lewy body dementia (DLB) [MIM:127750]. DLB is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Presence of Lewy bodies are the only essential pathologic features.

Disease: Deposition of fibrillar amyloid proteins intraneuronally as neurofibrillary tangles is characteristic of Alzheimer disease (AD). SNCA is a minor protein found within these deposits, but a major non amyloid component.

Disease: Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome), a rare neuroaxonal dystrophy, is histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions, glial inclusions and neurofibrillary tangles. SNCA is found in LB-like inclusions, glial inclusions and spheroids.

Similarity: Belongs to the synuclein family.

OMIM: 127750; phenotype. [NCBI / EBI]
163890; gene. [NCBI / EBI]
168600; phenotype. [NCBI / EBI]
168601; phenotype. [NCBI / EBI]
605543; phenotype. [NCBI / EBI]

Pathways:
KEGG pathway: Alzheimer's disease 05010
KEGG pathway: Neurodegenerative Disorders 01510
KEGG pathway: Parkinson's disease 05020

Products similar to SNCA protein:

IgG

Synuclein Alpha, IgG

alpha Synuclein (ready-to-use), IgG

alpha Synuclein [Syn204], IgG

Synuclein Alpha, IgG

alpha-Synuclein (clone 5C2), IgG

Peptide

Alpha Synuclein C-terminal Peptide, Peptide

Alpha -Synuclein Human, Protein

alpha-Synuclein E46K, Protein

alpha-Synuclein, Protein

alpha-Synuclein A30P, Protein

SUGGESTED PROTEIN REAGENTS - GenWay offers reagents to facilitate your research with cell-based assays, Mass Spectrometry, standards, calibrators, Western blot, cell culture, antibiotics, microwell substrates, and more!

BACKGROUND REFERENCES for SNCA PROTEIN:

Background references for antibody target are not specific to GenWay products

1. Ueda et al.,(1993) Proc. Natl.Acad.Sci. 90, 11282-11286.

Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.

Precautions: SNCA protein is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.

Important Notes: During shipment, small volumes of SNCA protein vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.

Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about SNCA protein, all related information, articles, resources about SNCA protein are being stored on our online database. Let us know if you have questions regarding this product.

Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed.

GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.

GenWay has a diverse line of recombinant protein expression platforms, including E. coli expression, Bacliovirus expression, yeast expression, and mammalian expression. Combining the technologies of bioinformatics, protein domain analysis, gene codon optimization, protein fusion, and protein expression in different host cells, GenWay can produce soluble and functional proteins. In particular, GenWay has the capability and vector systems for expression of difficult proteins such as proteases, kinases, glycosylated and membrane proteins. We have a very high success rate (almost 100%) and can deliver the proteins in a timely fashion. This is a core competency necessary for efficient and effective production of immunogens and affinity ligands for antibody production and purification. GenWay has over 300

recombinant proteins

offered in our catalog.



GenWay Biotech, Inc. 6777 Nancy Ridge Drive, San Diego, CA 92121 Tel: (858)458-0866 Fax: (858)458-0833 Email: sales@genwaybio.com www.genwaybio.com ©1998 - 2010 GenWay Biotech, Inc. - All Rights Reserved